What Is B2B2C in Healthcare? The Model Explained

B2B2C means an organization buys your product, but someone else — usually not that organization's own staff — is the person who actually has to use it. In healthcare, that "someone else" is a patient, an employee, or a health plan member, and the organization writing the check is a hospital, an employer, or an insurer. You aren't selling to one customer; you're selling to a buyer and separately earning an end user, and success with one doesn't guarantee success with the other.

Quick Answer: B2B2C in healthcare is a model where a business — an employer, health system, or payer — purchases your product, while a different person, the patient or employee, is the one who has to adopt and keep using it. You need a business case that survives procurement and a product good enough that someone with zero stake in the purchase decision keeps opening it. Losing either one loses the account.

Most founders don't choose B2B2C on purpose. They set out to build a straightforward B2C wellness app or a B2B clinical tool, and partway through customer discovery they discover the actual buyer and the actual user were never the same person to begin with. That discovery either happens early, while it's still cheap to redesign the go-to-market around it, or it happens after a contract is signed and usage never materializes — which is the far more expensive way to learn it.

How B2B2C Works: Buyer, Sponsor, and End User Roles

B2B2C works by splitting one sale into three functional roles that a normal B2C or B2B deal usually collapses into one or two. Mapping which entity holds each role — and whether one entity can hold more than one — is the first thing to do before you write a single line of go-to-market plan.

• The buyer is whoever signs the contract and controls the budget line your product gets paid from. In healthcare this is usually an employer's benefits team, a health plan's product or clinical leadership, or a health system's procurement and clinical operations group. The buyer evaluates your product against a business case: cost savings, reduced clinical risk, or an outcome they can defend at renewal.
• The sponsor is whoever makes the product visible and available to the end user — often the same entity as the buyer, but not always. An employer can be the buyer and its own sponsor by rolling your app into open enrollment. A health plan can be the buyer while a network of affiliated clinics acts as the sponsor that actually hands the product to patients. When buyer and sponsor split across two organizations, you've effectively added a fourth stakeholder to satisfy.
• The end user is the patient, employee, or member who opens the product and decides, session by session, whether it's worth their time. The end user rarely reads your pricing page, never sees the contract, and often doesn't know your company's name — they know whatever the buyer branded the benefit as.

Each role responds to a different kind of evidence. A buyer wants a defensible outcome and a clean renewal story. An end user wants the thing to work and to not feel like homework. A pitch built entirely around the buyer's ROI story can close a contract and still fail, because nobody designed for the person who has to open the app on a Tuesday night with no reminder from procurement telling them to.

B2B2C vs B2B vs B2C: How the Three Models Compare

B2B2C doesn't average the difficulty of the two simpler models — it stacks them. The table below lines up the dimensions that actually change how you build, sell, and get renewed.

The pattern worth sitting with: you still need the enterprise sale's evidence bar, and you still need the consumer product's habit-forming design — clearing one does nothing to clear the other. For a deeper walk through when to default to a pure B2B or B2C model instead, the B2B vs B2C decision framework for digital health covers the signals that tell you whether a hybrid is actually necessary for your idea or whether you're overcomplicating a simpler sale.

A Concrete Example: Selling a Wellbeing Product Through Employers

Picture a sleep and stress-coaching app — a hypothetical example, not a real company — sold as an employee benefit. The buyer is the employer's benefits leader, who evaluates the product against absenteeism, healthcare cost trend, or an engagement metric a broker helped define. The sponsor is usually that same employer, who rolls the app into open enrollment alongside dental and vision. The end user is an employee who has never heard of the company behind the app, received an email about a "new wellness benefit," and has close to zero intrinsic motivation to open it.

This single scenario contains two separate validation problems that founders often test as if they were one:

1. Will an employer actually buy this? That requires evidence a benefits leader can take to their own leadership — a plausible cost or productivity story, a clean security and compliance posture, and a pilot structure that doesn't ask for a full-year commitment up front. Selling digital health through employer benefits walks through the annual buying cycle and the broker relationships that gate this decision.
2. Will an employee actually use this? That requires the product to survive without the tailwind of personal financial stake. No employee is spending their own money here, so there's none of the self-selection that filters a paid consumer app down to motivated users only.

A pilot can succeed on the first question and fail on the second, and the contract still won't renew. Just as often, employees genuinely like the product while the employer can't produce a metric that justifies renewing it. Both failure modes are common, and neither shows up if you only test one side of the sale.

Why B2B2C Doubles Your Validation Work

B2B2C doubles your validation work because you're running two independent evidence-gathering efforts against two different definitions of success, on two different timelines — and a strong result on one side tells you almost nothing about the other.

The buyer-side validation looks like enterprise sales validation anywhere else: interviews with the actual budget holder, a business case that survives their internal scrutiny, and, ideally, a paid pilot rather than a free trial, since a business unwilling to pay anything for a pilot is unlikely to pay for a renewal. Before you even start this track, you need to know who the real buyer is, which in healthcare is rarely the obvious name on the org chart. Mapping providers, patients, and payers to find your real buyer is worth doing before you build a single slide of pitch deck, because "sell to healthcare" isn't a buyer — a specific benefits leader, medical director, or procurement team is.

The end-user validation looks more like consumer product validation: does a person with no financial stake in the purchase decision keep coming back, and does that usage resemble the number the buyer will be asked to defend at renewal. If you've only ever validated one side of a two-sided sale, the complete startup idea validation framework is worth revisiting specifically for the parts about testing real demand instead of polite interest — because polite interest is exactly what both a buyer's procurement team and a disengaged end user will offer you for free, right up until the moment either one has to actually commit.

The founders who get burned by B2B2C are rarely the ones who fail early. More often they validate the buyer thoroughly, sign the contract, and only then discover that end-user adoption was never tested at all — because it felt like a product problem to solve after the deal closed, not a validation problem to solve before it.

Key Takeaways

• B2B2C means the buyer and the end user are different people, which is the default shape of most digital health, not an exception to plan around later.
• Three roles matter, not two: the buyer who signs and pays, the sponsor who distributes access, and the end user who has to actually adopt — map which entity holds each one before you build your pitch.
• The model stacks difficulty rather than averaging it. You clear the full enterprise evidence bar and still have to earn habitual consumer usage separately.
• A signed contract is not validation of end-user demand. Test both sides independently, with real commitment — money or genuine usage — not polite interest from either.
• Know your real buyer before building your go-to-market. In healthcare that buyer is rarely the obvious one, and misidentifying it wastes as much time as picking the wrong business model entirely.
• Renewal, not the initial sale, is where B2B2C validation actually gets proven. A pilot that closes but doesn't drive usage will not renew, no matter how strong the sales conversation was.

Frequently Asked Questions

Is B2B2C the same thing as a marketplace business model?

No. A marketplace connects independent buyers and sellers who transact directly with each other, and the platform takes a cut. B2B2C is a single product sold to one paying business whose population then uses it — there's no direct transaction between the end user and a third party, and the end user typically pays nothing at all.

What does B2B2C look like outside of healthcare?

The same buyer/end-user split shows up anywhere a business purchases something on behalf of people who aren't part of the purchasing conversation: employee benefits platforms, software an IT department rolls out to non-technical staff, or a bank's app offered "free" to account holders. Healthcare is simply where this pattern is closest to universal rather than occasional.

How should you price a B2B2C healthcare product?

Price the contract around the buyer's business case — typically a per-member or per-employee-per-month rate tied to population size — not around what an individual end user would pay out of pocket, since the end user usually pays nothing directly. Structure at least part of the pricing or renewal terms around an engagement or outcome threshold, so the buyer's incentive to drive adoption stays aligned with yours.

Is B2B2C harder to raise funding for than a straightforward B2B or B2C startup?

It can be, mainly because investors have to underwrite two forms of risk instead of one — the enterprise sales motion and the consumer adoption curve — and a strong metric on one side doesn't reliably predict the other. The fix mirrors the fix for the model itself: show real, separate evidence for both the buyer's willingness to pay and the end user's willingness to engage, rather than leaning on one to imply the other.